# US 2019/0314469 A1 · Composition Comprising Thrombin-Treated Stem Cell-Derived Exosome For Treating Skin Wound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314469 A1
- Document ID: US20190314469A1
- Status: Published application
- Kind: A1
- Application number: 16/314,725
- Filed: 2017-06-27
- Published: 2019-10-17
- Earliest claimed: 2016-07-01
- Assignees: Samsung Life Public Welfare Foundation
- Applicants: Samsung Life Public Welfare Foundation
- Inventors: Yun Sil CHANG; Won Soon PARK; Dong Kyung SUNG; So Yoon AHN
- Web page: https://patentgrep.com/patent/US20190314469A1

## CPC

- A61K 38/4833: {Thrombin (3.4.21.5)}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/02: Suppositories; Bougies; Bases therefor; {Ovules}(apparatus for making A61J3/08; devices for introducing into the body A61M31/00)
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/12: Aerosols; Foams {(A61K9/0043, A61K9/0056, A61K9/006, A61K9/0073 take precedence; spray-films A61K9/7015)}
- A61K 9/70: Web, sheet or filament bases {; Films; Fibres of the matrix type containing drug (hollow drug-filled fibres A61K9/0092)}
- A61K 9/7023: {Transdermal patches and similar drug-containing composite devices, e.g. cataplasms (galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006)}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A61K 35/34: Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44)
- A61K 35/35: Fat tissue; Adipocytes; Stromal cells; Connective tissues (adipose-derived stem cells A61K35/28; collagen A61K38/39)
- A61K 35/50: Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- A61K 35/51: Umbilical cord; Umbilical cord blood; Umbilical stem cells
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0662: {Stem cells}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure relates to a pharmaceutical composition comprising an exosome derived from a thrombin-treated stem cell as an effective ingredient for preventing or treating a skin wound, a pharmaceutical formulation containing the same, and a production method thereof. Being a cell-free agent, an exosome-based therapeutic agent of the present disclosure has a low risk of carcinogenesis and no problems of graft rejection as well as being little liable to occur microvascular obstruction. The agent, which is not a cell, but a material isolated from a cell, can be subjected to medication development into an off-the-shelf product which allows for the reduction of production cost. The agent has the advantage of exhibiting outstanding angiogenesis and skin wound treatment effects even at a low concentration of exosomes thanks to the thrombin treatment effect.

## Claims

### Claim 1

A method of treating skin wound, comprising:
administering to a subject in need thereof an effective amount of exosomes derived from thrombin-treated stem cells.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the stem cells are selected from the group consisting of mesenchymal stem cells, human tissue-derived mesenchymal stromal cells, human tissue-derived mesenchymal stem cells and multipotent stem cells.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the mesenchymal stem cells are derived from umbilical cord, umbilical cord blood, bone marrow, fat, muscle, nerve, skin, amniotic membrane or placenta.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the treatment of skin wounds is caused by angiogenesis due to the promotion of the growth of vascular endothelial cells.

### Claim 5 (depends on 1)

The method according to claim 1, further comprising:
administering to a subject in need thereof an effective amount of a supplementary ingredient selected from group consisting of a culture medium, a cytokine, a growth factor and a gene.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the exosomes are increased in the expression of a growth factor, an immunoregulatory factor, an antioxidation factor or an angiogenesis factor.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the growth factor is a brain-derived neurotropic factor (BDNF), a fibroblast growth factor (FGF), a hepatocyte growth factor (HGF), a nerve growth factor (NGF), or a vascular endothelial growth factor (VEGF).

### Claim 8

A pharmaceutical formulation for treating skin wounds, comprising: a pharmaceutical formulation comprising one or more exosomes derived from thrombin-treated stem cells.

### Claim 9 (depends on 8)

The pharmaceutical formulation according to claim 8, which is an injection type, a suppository type, a spray type, a liquid type, or a patch type.

### Claim 10

A quasi-drug for improving skin wounds, comprising:
exosomes derived from thrombin-treated stem cells as an active ingredient.

### Claim 11 (depends on 10)

The quasi-drug according to claim 10, wherein the improvement of skin wounds is caused by angiogenesis.

### Claim 12 (depends on 10)

The quasi-drug according to claim 10, wherein the exosomes are increased in the expression of a growth factor, an immunoregulatory factor, an antioxidation factor or an angiogenesis factor.

### Claim 13 (depends on 10)

The quasi-drug according to claim 10, which is selected from the group consisting of a liquid, an ointment, a cream, a spray, a patch, a gel and an aerosol.

### Claim 14 (depends on 8)

A method of preparing the pharmaceutical formulation of claim 8, comprising:
(a) culturing stem cells and treating the stem cells with thrombin;
(b) isolating exosomes from the culture solution of Step (a); and
(c) preparing a formulation containing the exosomes isolated in Step (b) as an active ingredient.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the thrombin of Step (a) is contained in a medium at 1 to 1000 unit/mL.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the exosomes of Step (b) are isolated by centrifugation at 3,000 to 100,000 g for 10 minutes to 5 hours.

### Claim at position 17

17-18. (canceled)
